Codexis Inc - Company Profile
Powered by 
All the data and insights you need on Codexis Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Codexis Inc Strategy Report
- Understand Codexis Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Codexis Inc (Codexis) is a protein engineering company that discovers, develops and markets synthetic proteins for a wide range of applications. It sells biocatalysts for the commercial manufacture of pharmaceuticals and industrial enzymes and fine chemicals, and enzymes as biotherapeutics and for use in molecular diagnostics. The company identifies, optimizes and produces enzymes by using CodeEvolver, its proprietary protein engineering technology platform, which introduces mutation into genes to transform the enzymes that they produce. It also offers a range of biocatalyst solutions including robotic high-throughput screening, organic chemistry and process development, and genomic sequencing. The company serves pharmaceutical, food manufacturing, agricultural feed, consumer care, and chemical companies. Codexis is headquartered in Redwood City, California, the US.
Headquarters
United States of America
Address
200 Penobscot Dr, Redwood City, California, 94063-4718
Website
www.codexis.com
Telephone
1 650 4218100
No of Employees
174
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CDXS (NASD)
Revenue (2022)
$70.1M
-49.4%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-127%
(2022 vs 2021)
Market Cap*
$201.8M
Net Profit Margin (2022)
XYZ
-348.4%
(2022 vs 2021)
* As of and is in US$
Codexis Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Pharmaceutical Enzymes and Intermediates | - | - |
| Active Pharmaceutical Ingredients | Biocatalysis Solutions | Codex |
| Codex Screening Panels and Kits | Screening | Codexis |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In March, UC San Diego and Novonesis joined forces to pioneer Human Milk Oligosaccharide research. |
| 2024 | Contracts/Agreements | In February, the company entered into an agreement with Roche for an exclusive, global license for its newly engineered double-stranded DNA (dsDNA) ligase for next-generation sequencing (NGS) library preparation and its EvoT4 DNA ligase. |
| 2024 | Contracts/Agreements | In February, the company signed a loan facility agreement with Innovatus Capital Partners, LLC affiliate to expedite the development and improve the commercialization of the ECO Synthesis manufacturing platform for RNAi therapeutics. |
Competitor Comparison
| Key Parameters | Codexis Inc | BASF SE | Bayer AG | Johnson Matthey Plc | DSM-Firmenich AG |
|---|---|---|---|---|---|
| Headquarters | United States of America | Germany | Germany | United Kingdom | Switzerland |
| City | Redwood City | Ludwigshafen Am Rhein | Leverkusen | London | Kaiseraugst |
| State/Province | California | Rheinland-Pfalz | Nordrhein-Westfalen | England | - |
| No. of Employees | 174 | 111,991 | 99,723 | 12,666 | 29,301 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Byron L. Dorgan | Chairman | Executive Board | 2021 | 81 |
| Stephen Dilly | President; Director; Chief Executive Officer | Executive Board | 2022 | 63 |
| Sri Ryali | Chief Financial Officer | Senior Management | 2023 | 43 |
| Kevin Norrett | Chief Operating Officer | Senior Management | 2022 | 51 |
| Margaret Fitzgerald | General Counsel; Secretary; Chief Legal and Compliance Officer | Senior Management | 2022 | 53 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward